165-205

Overview

Status: Active, not recruiting
Keywords: PKU , phenylketonuria , PEG-PAL , PAL
IRB Number: 00056411
Specialty: Pediatric Genetics
Sub Specialties:

Brief Summary

 

This study will be a Phase 2, multi-center, open-label, dose-finding study to evaluate safety, efficacy and tolerability of rAvPAL-PEG in patients with PKU for a treatment period of 24 weeks. Approximately 24 rAvPAL-PEG-naïve eligible patients with PKU will be enrolled in the study. The total study duration for an individual patient will be up to 29 weeks: up to 4 weeks screening, 24 weeks of treatment with rAvPAL-PEG, and 1 week for post-treatment safety follow-up. Upon completion of the study, all patients will be offered to enroll in the long-term extension study PAL-003. 

 

 
The primary objective of the study is:
• To identify a safe and efficacious dosing regimen of rAvPAL-PEG by evaluating multiple schedules involving bolus, induction, titration, and maintenance dosing.
 
The secondary objectives of the study are:
• To evaluate immune response of multiple SC doses of rAvPAL-PEG on reduction of blood Phe concentrations in patients with PKU.
• To evaluate pharmacokinetic (PK) profile of multiple SC doses of rAvPAL-PEG on reduction of blood Phe concentrations in patients with PKU.
 
The exploratory objectives of the study are as follows:
• To assess the relationship between change in blood Phe concentration and diet following administration with rAvPAL-PEG in patients with PKU.
• To assess the relationship of change in metabolic panel from baseline to end of study following administration of rAvPAL-PEG in patients with PKU.

 

Principal Investigator: Nicola Longo
Department: Pediatric Genetics
Co Investigator: Dave Viskochil
Co Investigator: Ashley Warnock
Co Investigator: Lorenzo Botto

Contact Information

Name:Carrie Bailey
Phone: 8015873605
Email: carrie.bailey@hsc.utah.edu

Inclusion Criteria

 

 

1. A diagnosis of PKU, with the following: 

• Current blood Phe concentration of ≥ 600 μmol/L at Screening. 

• Average blood Phe concentration of ≥ 600 μmol/L over the past 6 months, using available data. 

• Naïve to prior treatment with rAvPAL-PEG. 

2. Evidence that the patient is a non-responder to KUVANtreatment (ie, 4 weeks of treatment with 20 mg/kg/day of KUVAN™, insufficient response per investigator determination, unsuitable for KUVAN™ per Investigator determination, and treatment end date ≥ 2 days prior to Day 1 [ie, first dose]). Patients who have had a previous response to KUVANtreatment but are not currently taking KUVANbecause of noncompliance and have been off treatment for ≥ 4 months prior to Screening are eligible for participation. 

3. Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any research-related procedures. In the case of participants under the age of 18, a parent or legal guardian may provide written informed consent (and, if required, the patient will provide written assent). 

4. Willing and able to comply with all study procedures. 

5. Between the ages of 16 and 70 years, inclusive. 

6. Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy. 

7. Sexually active patients must be willing to use an acceptable method of contraception while participating in the study. 

8. Maintained a stable diet with no significant modifications during the 4 weeks preceding the administration of study drug and willing to continue with the diet while on study so as to avoid potential variability of response due to variations in dietary intake. 

9. In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening. 

 

 

 

 

Exclusion Criteria

 

 

1. Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments. 

2. Use of any medication that is intended to treat PKU, including use of large neutral amino acids, within 2 days prior to the administration of study drug. 

3. Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera®, within 3 months prior to Screening and during study participation. 

4. A prior reaction that included systemic symptoms (eg, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to a PEG-containing product. Patients with a prior systemic reaction of generalized rash may be eligible for participation per the discretion of the Principal Investigator in consultation with the Sponsor’s Medical Monitor. 

5. A positive test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, or hepatitis C antibody. 

6. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study. 

7. Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease). 

8. Any condition that, in the view of the PI, places the patient at high risk of poor treatment compliance or of not completing the study. 

9. Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal. 

10. Creatinine > 1.5 times the upper limit of normal.